QuidelOrtho Corporation (NASDAQ:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that its board of directors has authorized the repurchase of up to $300 million of shares of QuidelOrtho’s common stock over the next two years.
China Revs Up EV Sales With Up To $1,380 Trade-In Subsidy For Old Cars
The subsidy program will be applicable till the end of 2024 and is aimed at countering weak consumer sentiment within the country.
